Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; silicon dioxide; magnesium stearate; maize starch; titanium dioxide; potable water; gelatin; brilliant scarlet 4r; patent blue v; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggests that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of acute phase cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal canidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oesophageal canidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks. (see adverse reactions).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; silicon dioxide; magnesium stearate; maize starch; titanium dioxide; potable water; gelatin; propylene glycol; purified water; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide; iron oxide black - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggests that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of acute phase cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal canidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oesophageal canidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea crur

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole, quantity: 100 mg - capsule, hard - excipient ingredients: lactose monohydrate; maize starch; sodium lauryl sulfate; silicon dioxide; magnesium stearate; titanium dioxide; potable water; gelatin; patent blue v; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggests that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of acute phase cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal canidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oesophageal canidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks. (see adverse reactions).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: macrogol 4000; hypromellose; colloidal anhydrous silica; magnesium stearate; propylene glycol; microcrystalline cellulose; lactose monohydrate; purified talc; titanium dioxide; croscarmellose sodium - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression, in adults, of chronic, recurrent urinary tract infection.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: lactose monohydrate; maize starch; sodium lauryl sulfate; silicon dioxide; magnesium stearate; titanium dioxide; potable water; gelatin; patent blue v; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggests that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of acute phase cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal canidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oesophageal canidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive pedis infections in immunocompetent patients in whom topical therapy is not practical treatment option. usually, topical therapy should be attempted first because oral therapy has less favourable ratio of benefits to risks. (see adverse reactions).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: povidone; hyprolose; maize starch; poloxamer; colloidal anhydrous silica; purified talc; magnesium stearate; glucose; titanium dioxide; hypromellose; propylene glycol - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. non-gonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children weighing greater than 40 kg caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organisms susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: povidone; hyprolose; maize starch; poloxamer; colloidal anhydrous silica; purified talc; magnesium stearate; glucose; titanium dioxide; hypromellose; propylene glycol - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. non-gonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children weighing greater than 40 kg caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organisms susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note. specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infection.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ipratropium bromide monohydrate -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ipratropium bromide monohydrate -